Login / Signup

Postapproval Comparative Safety Study of Tofacitinib and Biological Disease-Modifying Antirheumatic Drugs: 5-Year Results from a United States-Based Rheumatoid Arthritis Registry.

Joel M KremerClifton O BinghamLaura C CappelliJeffrey D GreenbergAnn M MadsenJamie GeierJose L RivasAlina M OnofreiChristine J BarrDimitrios A PappasHeather J LitmanKimberly J DandreoAndrea B ShapiroCarol A ConnellArthur Kavanaugh
Published in: ACR open rheumatology (2021)
In this registry analysis, both cohorts had similar MACE, SIE, malignancy, death, and VTE rates; HZ rates were higher for tofacitinib initaitors than for bDMARD initiators.
Keyphrases
  • rheumatoid arthritis
  • disease activity
  • venous thromboembolism
  • interstitial lung disease
  • ankylosing spondylitis
  • ulcerative colitis
  • rheumatoid arthritis patients
  • drug induced